PDE4B (Gene)

Synonyms:DPDE4, ENTREZ:5142, HGNC:8781, MIM:600127, NM_001037339, NM_001037340, NM_001037341, NM_001297440, NM_001297441, NM_001297442, NM_002600, NP_001032416, NP_001032417, NP_001032418, NP_001284369, NP_001284370, NP_001284371, NP_002591, PDE4B, PDEIVB, XM_005270924, XM_005270925, XM_006710680, XM_017001445, XP_005270981, XP_005270982, XP_006710743, XP_016856934, phosphodiesterase 4B
Omim:OMIM:600127
Id:ENSG00000184588
Hgnc:HGNC:8781
Entrez:5142
Description:phosphodiesterase 4B
This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. The encoded protein regulates the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder. Alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2014]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PDE4B's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PDE4B.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PDE4B.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PDE4B.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PDE4B.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.